News Quantified

ACXP – acurx pharmaceuticals, inc. (US:NASDAQ)

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

4/23

10:57 am

acxp

Medium

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV [Yahoo! Finance]

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00. They now have a "buy" rating on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}